查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197326

颅内动脉瘤市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Intracranial Aneurysm Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，颅内动脉瘤市场预计将以 4.5% 的复合年增长率登记。

COVID-19 大流行通过直接影响需求和生产、扰乱供应链并增加公司的财务负担，严重影响了颅内动脉瘤市场。. 在此期间，脑部手术也被推迟或取消，以遏制病毒的传播。 受灾最严重的国家，包括美国、俄罗斯、印度、巴西、法国、英国、意大利和西班牙，神经外科手术减少了 55%。 然而，根据基准年 1 月发表的“COVID-19 和医院评论”，高达 36% 的住院 COVID-19 患者出现神经系统症状，伴有少量缺血性和出血性梗死。已经发生。 这些结果表明 COVID-19 可能会提高神经行业的销售额。 因此，这些因素为市场在短时间内的增长创造了有利可图的机会，并为 COVID-19 后的主要参与者提供了有利可图的机会。

患有高血压和血管外伤的患者增加也是推动颅内动脉瘤市场的因素之一。 高血压会显着增加脑动脉瘤的风险。 由于高血压和吸烟，很大一部分人口有患脑动脉瘤的风险。 根据世卫组织基准年更新，全球估计有 12.8 亿 30-79 岁的成年人患有高血压，其中大多数（三分之二）生活在低收入和中等收入国家。 我们推测这种趋势将在预测期内持续，导致颅内动脉瘤。 因此，未来市场有望大幅增长。 此外，全球人口老龄化正在加速。

此外，根据基准年 10 月发表的“老年患者未破裂脑动脉瘤：主要挑战和管理”研究，据说老年人未破裂脑动脉瘤的患病率正在迅速增加。 根据世界人口展望，世界 65 岁及以上人口的比例预计将从今年的 10% 上升到 2050 年的 16%。 到 2050 年，全球 65 岁及以上人口的数量将是 5 岁以下儿童数量的两倍以上，几乎与 12 岁以下儿童数量持平。 因此，随着老年人口的增加，颅内动脉瘤的数量预计会增加。 预计市场在预测期内将出现更好的增长。

製造商为满足对创新产品不断增长的需求而增加产品推出，预计将推动市场增长。 例如，印度美敦力于今年6月推出了具有Conformite Europeenne（CE）标誌的第4代脑动脉瘤血管内治疗分流器“Pipeline Vantage with Shield Technology”。 此外，2022 年 2 月，Viz.ai 软件获得了美国食品和药物管理局的许可，可以自动检测脑动脉瘤。 这些因素可能会推动全球对颅内动脉瘤治疗的需求。

然而，高昂的治疗费用预计会阻碍颅内动脉瘤市场的增长。

颅内动脉瘤市场趋势

颅内动脉瘤市场，血管内栓塞事业部有望占据较大份额

预计未来血管内弹簧圈会有健康的发展。 它是一种微创技术，使用导管治疗脑动脉瘤并阻止血液流入动脉。 与这种治疗相关的优势，例如容易进入椎基底动脉系统、远处有多个动脉瘤，以及与其他治疗相比恢復时间更短，正在推动这一领域的增长。

此外，全球中风发病率不断上升，这可能会导致血管破裂导致颅内动脉瘤，这也推动了市场收入的增长。

例如，根据世界中风组织 (WSO) 于 2022 年发布的数据，大约有 1200 万人 (12,224,551) 经历过中风。 该组织表示，每年有超过 1220 万例新中风，在全球范围内，25 岁以上的人中有四分之一在其一生中会经历中风。 因此，全球中风患者负担的增加预计将推动市场增长。

此外，预计主要参与者增加产品发布将提振市场。 例如，2022 年 6 月，Rapid Medical 宣布扩大其在美国的产品组合和首个 Numen 弹簧圈栓塞术。 Rapid Medical 与 MicroPort Scientific Corporation 的子公司 MicroPort NeuroTech 签订了独家经销协议。 因此，预计产品发布将在预测期内推动该细分市场的增长。

因此，上述所有因素都有望在预测期内提振该细分市场。

北美占据了很大的市场份额，预计在预测期内也会如此

由于人口老龄化加剧、颅内动脉瘤患病率增加、对微创手术的需求增加以及高血压和中风的发病率，预计北美在颅内动脉瘤市场中占有很大的市场份额。

中风是一种出现症状后需要尽快治疗的疾病。 因此，快速治疗的可用性是美国高存活率的重要因素。 根据疾病预防控制中心 2022 年 4 月发布的数据，超过 795,000 名美国人中风。 其中，已知每年发生 610,000 例新病例。 统计数据显示，中风是美国主要的死亡原因之一，在美国每 40 秒就有一人罹患中风。 随着中风患者数量的增加，对其治疗的需求也在增加，预计将推动颅内动脉瘤市场。

由于创新疗法的开发、行业参与者的本地扩张以及新疗法的进入，预计北美在预测期内将保持类似的主导地位。 2022 年 9 月，Vesalio 宣布美国食品药品监督管理局 (FDA) 批准 NeVa VS 用于治疗动脉瘤破裂后的脑血管痉挛。

因此，上述所有因素都有望在预测期内提振市场。

颅内动脉瘤市场竞争者分析

颅内动脉瘤市场竞争适中，由几家大型企业组成。 目前主导市场的公司包括 Stryker、B. Braun Melsungen AG、MicroPort Scientific Corporation、Medtronic、Terumo Corporation、Integra LifeSciences Corporation、Johnson & Johnson 和 RAUMEDIC AG。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 对微创手术的需求不断增加
    • 脑动脉瘤患病率上升
    • 技术进步
  • 市场製约因素
    • 高昂的治疗费用
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按类型
    • 血管内弹簧圈
    • 手术剪报
    • 分流器
    • 其他类型
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他最终用户
  • 按地区细分
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Stryker
    • B. Braun Melsungen AG
    • MicroPort Scientific Corporation
    • Medtronic
    • Terumo Corporation
    • Integra LifeSciences Corporation
    • Johnson & Johnson
    • RAUMEDIC AG
    • Microvention Inc.
    • Codman Neuro（Integra Lifesciences）

第7章 市场机会今后动向

简介目录
Product Code: 71255

The intracranial aneurysm market is expected to register a CAGR of 4.5% during the forecast period.

The COVID-19 pandemic severely impacted the market for intracranial aneurysms by directly affecting demand and production, disrupting the supply chain, and increasing the financial burden on firms. Brain surgeries were postponed or even canceled during this timeframe to reduce the spread of the virus. In worst-affected nations, such as the United States, Russia, India, Brazil, France, the United Kingdom, Italy, and Spain, neurosurgical operations fell by 55%. However, according to a study published in January of the base year titled "COVID-19 and Hospital: A review," up to 36% of hospitalized COVID-19 patients experienced neurological symptoms, and there were several ischemic and hemorrhagic infarctions. These findings suggested COVID-19 may enhance sales in the neurology industry. Thus, these factors created lucrative opportunities for the market to grow shortly, providing profitable opportunities for key players post-COVID-19.

The increasing number of patients suffering from high blood pressure and trauma to blood vessels is another factor driving the market for intracranial aneurysms. Hypertension significantly increases the risk of a brain aneurysm and other diseases. A large percentage of the population is at risk of developing brain aneurysms due to high blood pressure and smoking. As per the WHO updates from the base year, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, with most (two-thirds) living in low- and middle-income countries. It is estimated that this trend will continue to rise even in the forecast period and lead to intracranial aneurysms. Thus, the market is expected to experience substantial growth in the future. In addition, the global population is aging at an accelerating pace.

Moreover, according to a study published in October of the base year titled "Unruptured Cerebral Aneurysms in Elderly Patients: Key Challenges and Management," the prevalence of unruptured brain aneurysms in elderly patients was rapidly increasing in patients aged 70 years or older. According to the World Population Prospects, this year, the share of the global population aged 65 years or above is projected to rise from 10% to 16% in 2050. By 2050, the number of people aged 65 years or over worldwide is projected to be more than twice the number of children under age five and about the same as that of children under age 12. Therefore, with the increase in the elderly population, intracranial aneurysms are expected to increase. The market is expected to show better growth over the forecast period.

The increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive the market's growth. For instance, in June this year, India Medtronic launched Conformite Europeenne (CE) marked fourth-generation flow diverter, Pipeline Vantage with Shield Technology, for endovascular treatment of brain aneurysms. Moreover, in February 2022, Viz.ai software received United States Food and Drug Administration clearance for automatically spotting brain aneurysms. Such factors potentially drive the demand to adopt intracranial aneurysm treatments worldwide.

However, the high cost of treatment is expected to hamper the growth of the intracranial aneurysm market.

Intracranial Aneurysm Market Trends

Endovascular Coiling Segment is Expected to Hold a Significant Share in the Intracranial Aneurysm Market

Endovascular coiling is estimated to witness healthy growth in the future. It is a minimally invasive technique wherein a catheter is used to treat the brain aneurysm by preventing blood from getting into arteries. Benefits associated with this procedure, such as easy access to the vertebrobasilar system, multiple aneurysms in distant areas, and shorter recovery time compared to other procedures, propelling the segment's growth.

In addition, the growing number of strokes worldwide has a high chance of rupturing blood vessels and leading to intracranial aneurysms, thus promoting revenue growth in the market.

For instance, according to data published by World Stroke Organization (WSO) in 2022, About 12 million (12,224,551) people experienced a stroke. The organization stated that there are more than 12.2 million new strokes each year, and globally, one in four people after 25 years of age experience a stroke in their lifetime. Hence, the increasing burden of patients with stroke globally is expected to drive the market's growth.

Moreover, increasing product launches by key players are expected to boost the market. For instance, in June 2022, Rapid Medical announced the expansion of its portfolio in the United States and the first Numen coil embolization procedure. Rapid Medical has an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation. Thus, product launches are expected to boost the market segment's growth over the forecast period.

Thus, all factors mentioned above are expected to boost the segment over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the intracranial aneurysm market due to the increasing aging population, increasing prevalence of intracranial aneurysms, rising demand for minimally invasive procedures, and incidences of hypertension and stroke.

Stroke is a condition where treatment must be given as early as possible after the onset of symptoms. Hence, the availability of quick treatment is a key factor responsible for the high survival rate in the United States. According to the statistics published by the CDC in April 2022, more than 795,000 Americans have strokes. Of this, 610,000 are found to be new cases each year. Statistics revealed stroke is one of the causes of death in the United States; every 40 seconds, people from the United States have a stroke. The increasing number of patients suffering from stroke is expected to increase the demand for its treatment, driving the market for intracranial aneurysms.

North America is expected to observe the same dominance during the forecast period due to the development of innovative therapies, major industry players' local presence, and new therapies' entry. In September 2022, Vesalio announced the Food and Drug Administration's approval of the NeVa VS to treat cerebral vasospasm after aneurysmal rupture.

Thus, all factors above are expected to boost the market over the forecast period.

Intracranial Aneurysm Market Competitor Analysis

The intracranial aneurysm market is moderately competitive and consists of several major players. Some companies currently dominating the market are Stryker, B. Braun Melsungen AG, MicroPort Scientific Corporation, Medtronic, Terumo Corporation, Integra LifeSciences Corporation, Johnson & Johnson, and RAUMEDIC AG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand of Minimally Invasive Procedures
    • 4.2.2 Rising Prevalence of Brain Aneurysm
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Endovascular Coiling
    • 5.1.2 Surgical Clipping
    • 5.1.3 Flow Diverters
    • 5.1.4 Other Types
  • 5.2 By End-user
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Other End-users
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Stryker
    • 6.1.2 B. Braun Melsungen AG
    • 6.1.3 MicroPort Scientific Corporation
    • 6.1.4 Medtronic
    • 6.1.5 Terumo Corporation
    • 6.1.6 Integra LifeSciences Corporation
    • 6.1.7 Johnson & Johnson
    • 6.1.8 RAUMEDIC AG
    • 6.1.9 Microvention Inc.
    • 6.1.10 Codman Neuro (Integra Lifesciences)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS